Early Access — free while we kick the tires
EdgarHawk

Bunnage Mark E.

EVP, Chief Scientific Officer

Officer
1 filing analyzed · 1 company · Latest 2026-02-19

Companies

Company Buys Sells Direction
VERTEX PHARMACEUTICALS INC / MA VRTX 0 4 Net selling

Activity

February 2026
medium
Sell
3,619 shares
$1,752,704
Significance 5/10

VRTX EVP Mark Bunnage sells 3,619 shares in 2 transactions for $1,752,703.78; retains 8,486 shares post-sale

Mark Bunnage, EVP and Chief Scientific Officer, executed 2 separate sales totaling 3,619 shares for $1,752,703.78 at blended average price $484.31. His post-transaction holdings of 8,486 shares represent a 29.9% reduction from prior holdings of 12,105 shares. The transactions occurred on 2026-02-17 and 2026-02-18 at $489.46 and $473.68 respectively, while the current stock price stands at $469.27—below both transaction prices. The stock has risen 6.2% over 30 days and 10.0% over 90 days, positioning this sales activity within a period of positive momentum for VRTX, which carries a P/E of 14.60 and recently reported quarterly revenue of $3,076,400,000.00 with net income of $1,082,900,000.00.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access